Freeline Therapeutics Statistics
Share Statistics
Freeline Therapeutics has 4.36M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 4.36M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 10.36K, so 0.24% of the outstanding
shares have been sold short.
| Short Interest | 10.36K |
| Short % of Shares Out | 0.24% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.32 and the forward
PE ratio is null.
Freeline Therapeutics's PEG ratio is
0.01.
| PE Ratio | -0.32 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/FCF Ratio | -0.33 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Freeline Therapeutics has an Enterprise Value (EV) of -13.18M.
| EV / Sales | 0 |
| EV / EBITDA | 0.14 |
| EV / EBIT | 0.17 |
| EV / FCF | 0.15 |
Financial Position
The company has a current ratio of 2.18,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.18 |
| Quick Ratio | 1.61 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.07 |
| Interest Coverage | 9.55 |
Financial Efficiency
Return on Equity is -169.75% and Return on Invested Capital is -169.45%.
| Return on Equity | -169.75% |
| Return on Assets | -102.69% |
| Return on Invested Capital | -169.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-585,342.11 |
| Employee Count | 152 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.1 |
Taxes
| Income Tax | 368K |
| Effective Tax Rate | -0.42% |
Stock Price Statistics
The stock price has increased by 0.15% in the
last 52 weeks. The beta is 0.66, so Freeline Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.66 |
| 52-Week Price Change | 0.15% |
| 50-Day Moving Average | 6.42 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 61.01 |
| Average Volume (20 Days) | 28,144 |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.74M |
| Operating Income | -98.45M |
| Net Income | -88.97M |
| EBITDA | -97.17M |
| EBIT | -98.92M |
| Earnings Per Share (EPS) | -22.52 |
Full Income StatementBalance Sheet
The company has 47.28M in cash and 5.92M in
debt, giving a net cash position of 41.35M.
| Cash & Cash Equivalents | 47.28M |
| Total Debt | 5.92M |
| Net Cash | 41.35M |
| Retained Earnings | -445.35M |
| Total Assets | 49.22M |
| Working Capital | 16.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -78.22M
and capital expenditures -7.01M, giving a free cash flow of -85.24M.
| Operating Cash Flow | -78.22M |
| Capital Expenditures | -7.01M |
| Free Cash Flow | -85.24M |
| FCF Per Share | -21.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
